The overall goal of the Leukemia SPORE Developmental Research Program (LSDRP) is to recruit and support developmental research projects in leukemia for future peer-reviewed funding and/or future independent SPORE projects. The types of studies to be supported include projects in basic research, clinical research, epidemiologic studies, and cancer prevention and control research in leukemia. Projects supported under the LSRDP will expand the scope of translational research and increase the number of investigators committed to leukemia research. The LSDRP will work in tandem with the Career Development Program to assist in the development of junior investigators and in the recruitment and mentoring of minority investigators. To accomplish these goals, the following specific aims are proposed 1. To support developmental research projects in leukemia for future incorporation as full SPORE projects and for applications for other major peer-reviewed funding. New research projects will be solicited and funded using developmental funds. A total of $175,000 has been committed annually to this program (including $125,000 per year of matching funds from institutional sources). These funds will be used to support 3-5 developmental projects per year ranging from $30,000 to $60,000 throughout the life of the SPORE. 2. Foster collaborations between basic and clinical researchers. The LSDRP chairs will facilitate interaction between basic and clinical researchers through shared weekly meetings, the annual SPORE retreat, and small group meetings. 3. To provide mentoring to junior faculty. Ail investigators submitting developmental research projects will receive a written scientific and statistical review, and the LSDRP chairs will be available to discuss the projects in detail. Where appropriate, mentors will be identified to work with junior faculty.
The Developmental Research Program will recruit and support innovative early-stage research in leukemia.
|White, Brian S; DiPersio, John F (2014) Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer 120:1134-44|
|Mesa, Ruben A; Kiladjian, Jean-Jacques; Verstovsek, Srdan et al. (2014) Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 99:292-8|
|Hopman, Rusudan K; DiPersio, John F (2014) Advances in stem cell mobilization. Blood Rev 28:31-40|
|Welch, John S (2014) Mutation position within evolutionary subclonal architecture in AML. Semin Hematol 51:273-81|
|Ramsingh, Giridharan; Westervelt, Peter; McBride, Ali et al. (2014) Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML. Int J Hematol 99:272-8|
|Giralt, Sergio; Costa, Luciano; Schriber, Jeffrey et al. (2014) Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations. Biol Blood Marrow Transplant 20:295-308|
|Anthony, Bryan A; Link, Daniel C (2014) Regulation of hematopoietic stem cells by bone marrow stromal cells. Trends Immunol 35:32-7|
|Welch, John S; Niu, Haixia; Uy, Geoffrey L et al. (2014) A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. Am J Hematol 89:E103-8|
|Calvi, Laura M; Link, Daniel C (2014) Cellular complexity of the bone marrow hematopoietic stem cell niche. Calcif Tissue Int 94:112-24|
|Jacoby, Meagan A; Martin, Michael G; Uy, Geoffrey L et al. (2014) Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. Am J Hematol 89:487-92|
Showing the most recent 10 out of 12 publications